354 related articles for article (PubMed ID: 16312398)
1. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Nord CE
J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
[No Abstract] [Full Text] [Related]
2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
3. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
Banic S
APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
[No Abstract] [Full Text] [Related]
5. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
[TBL] [Abstract][Full Text] [Related]
6. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
Grace ME; Fu KP; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the activity of first and second generation cephalosporins and their combinations with beta-lactamase inhibitors against Bacteroides fragilis.
Martin MA; Liebana J; Castillo AM; Gutierrez J; Piédrola G
Microbios; 1991; 67(272-273):195-202. PubMed ID: 1779879
[TBL] [Abstract][Full Text] [Related]
8. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
9. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
10. The activity of a sulphone beta-lactamase inhibitor, YTR 830.
Moosdeen F; Williams J; Yamabe S
Chemioterapia; 1987 Jun; 6(2 Suppl):206-7. PubMed ID: 2855613
[No Abstract] [Full Text] [Related]
11. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
13. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
Paniagua GL; Monroy E; García O; Vaca S
Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
Ling TK; Ying CM; Lee CC; Liu ZK
Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
17. Effect of five irreversible inhibitors on beta-lactamase from Shigella flexneri UCSF-129.
Campos M; Alarcón MA; González H; Sánchez R
Microbios; 1993; 76(308):171-9. PubMed ID: 8302198
[TBL] [Abstract][Full Text] [Related]
18. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
Thomson JM; Distler AM; Bonomo RA
Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
[TBL] [Abstract][Full Text] [Related]
20. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
Cullmann W; Binder S; Stieglitz M
Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
